ArticleThe oncologist2022

Phase I Trial of a Third Generation EGFR Mutant-Selective Inhibitor (D-0316) in Patients with Advanced Non-Small Cell Lung Cancer.

Hong Jian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.